Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Triptorelin (Trelstar) vs Ziconotide (Prialt)
An educational, source-based comparison of Triptorelin (Trelstar) and Ziconotide (Prialt) — how each peptide works, what it's researched for, and what to know before going deeper.
Decapeptide GnRH agonist that initially stimulates then desensitizes pituitary GnRH receptors, suppressing LH, FSH, and downstream gonadal steroid production after the initial flare.
- Advanced prostate cancer
- Central precocious puberty (international)
- Endometriosis (international)
- • FDA-approved.
- • Initial testosterone flare; consider antiandrogen pretreatment.
- • Hot flashes, bone density loss with chronic use.
Synthetic ω-conopeptide for severe chronic pain via intrathecal infusion.
Synthetic version of ω-conotoxin MVIIA from cone snail Conus magus; selectively blocks N-type voltage-gated calcium channels on primary afferent nerve terminals in the spinal dorsal horn, inhibiting nociceptive neurotransmitter release.
- Severe chronic pain refractory to systemic analgesics, intrathecal morphine
- • FDA-approved.
- • Black-box warning for severe psychiatric and neurologic effects.
- • Contraindicated in history of psychosis.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Triptorelin (Trelstar) | Triptorelin vs leuprolide in prostate cancer | Urology | 2002 | Comparable testosterone suppression efficacy. |
| Ziconotide (Prialt) | Ziconotide intrathecal pivotal trial | JAMA | 2004 | Significant pain relief in opioid-refractory chronic pain. |
Side-effect & safety grid
- FDA-approved.
- Initial testosterone flare; consider antiandrogen pretreatment.
- Hot flashes, bone density loss with chronic use.
- FDA-approved.
- Black-box warning for severe psychiatric and neurologic effects.
- Contraindicated in history of psychosis.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Triptorelin (Trelstar) vs Ziconotide (Prialt) — Key differences
- Class: Triptorelin (Trelstar) is classified as GnRH Agonist · Oncology, while Ziconotide (Prialt) is N-type Calcium Channel Blocker · Analgesic.
- Primary research focus: Triptorelin (Trelstar) — advanced prostate cancer; Ziconotide (Prialt) — severe chronic pain refractory to systemic analgesics, intrathecal morphine.
- Tag: FDA-Approved · Oncology vs FDA-Approved · Pain.